IDORSIA AG SF-,05 WKN A2DTEB | ISIN CH0363463438 | Aktie Watchlist Musterdepot Alert Factsheet 12.11.24 22:59:35 RT Bid: 1,001 EUR | Ask: 1,033 EUR 1,001 EUR +0,20 % (+0,002) Lang & Schwarz SIX Swiss Exchange Nasdaq Other OTC Baader Bank (Baadex) Lang & Schwarz EUREX Hamburg München Verkaufen Kaufen Übersicht Chart-Pro Analysen Nachrichten Kurse & Handelsplätze Letzte Umsätze 03.06.24 GNW-Adhoc: New data with daridorexant to be presented at SLEEP 2024 31.05.24 GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 23.05.24 GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders 21.05.24 GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors 21.05.24 GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor 21.05.24 GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value 14.05.24 GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call 06.05.24 GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds 01.05.24 GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond 26.04.24 GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension 23.04.24 GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting 17.04.24 GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting 11.04.24 GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs 22.03.24 GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires 20.03.24 GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives